QUESTCOR PHARMACEUTICALS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-12-11: Form 8-K; Period of report 2013-12-11; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2013-12-11: Form 8-K; Period of report 2013-12-10; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2013-11-14: Form 8-K; Period of report 2013-11-09; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2013-11-04: Form 8-K; Period of report 2013-10-29; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-12-11 | 8-K | 2013-12-11 | 7.01 Regulation FD Disclosure | 7.01 Commencing on December 11, 2013, Questcor Pharmaceuticals, Inc. will utilize an updated presentation for investor relations purposes. | d640390d8k.htm |
| 2013-12-11 | 8-K | 2013-12-10 | 7.01 Regulation FD Disclosure | 7.01 On December 10, 2013, the Board of Directors of Questcor Pharmaceuticals, Inc. (“Questcor” or the “Company”) unanimously voted to establish two new committees of the Board: a Science Committee and a Strategic Advisory Committee. | d639969d8k.htm |
| 2013-11-14 | 8-K | 2013-11-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 9, 2013 the Board of Directors (the “Board”) of Questcor Pharmaceuticals, Inc. (the “Company”) added Mr. G. Kelly Martin to the Board. | d627323d8k.htm |
| 2013-11-04 | 8-K | 2013-10-29 | 2.02 Results of Operations and Financial Condition | 2.02 On October 29, 2013, Questcor Pharmaceuticals, Inc. (the “Company”) announced via press release certain operating and financial results for the quarter ended September 30, 2013. | d622123d8k.htm |
| 2013-10-07 | 8-K | 2013-10-03 | 7.01 Regulation FD Disclosure | 7.01 On October 3, 2013, Questcor Pharmaceuticals, Inc. (the “Company”) posted an updated version of a letter from the Company’s Chief Executive Officer regarding its corporate history to its website, located at www.questcor.com. | d609224d8k.htm |
| 2013-08-06 | 8-K | 2013-08-06 | 7.01 Regulation FD Disclosure | 7.01 Commencing on August 6, 2013, Questcor Pharmaceuticals, Inc. will utilize an updated presentation for investor relations purposes. | d580909d8k.htm |
| 2013-08-06 | 8-K | 2013-07-30 | 2.02 Results of Operations and Financial Condition | 2.02 On July 30, 2013, Questcor Pharmaceuticals, Inc. (the “Company”) announced via press release certain operating and financial results for the quarter ended June 30, 2013. | d580892d8k.htm |
| 2013-08-05 | 8-K | 2013-07-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 31, 2013, the Board of Directors (the “Board”) appointed Michael H. Mulroy as Executive Vice President, Chief Financial Officer, General Counsel and Corporate Secretary. | d580361d8k.htm |
| 2013-07-12 | 8-K | 2013-07-11 | 7.01 Regulation FD Disclosure | 7.01 On July 11, 2013, Questcor Pharmaceuticals, Inc. (the “Company”) issued a press release providing information on its intent to initiate a pilot commercialization effort for H.P. Acthar® Gel (repository corticotropin injection) (“Acthar”) for the treatment of respiratory manifestations of symptomatic sarcoidosis, a potentially serious, difficult-to-treat disorder already included on the Acthar label. | d567566d8k.htm |
| 2013-06-11 | 8-K | 2013-06-11 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.03 Pursuant to the Agreements, Questcor is obligated to pay Novartis future consideration of not less than $75 million. 8.01 On June 11, 2013, Questcor issued a press release announcing the closing of the transactions contemplated by the Agreements. | d552318d8k.htm |
| 2013-06-11 | 8-K | 2013-06-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 8, 2013 the Board of Directors (the “Board”) of Questcor Pharmaceuticals, Inc. (the “Company”) added Mr. Angus C. Russell to the Board. | d551969d8k.htm |
| 2013-05-30 | 8-K | 2013-05-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On May 23, 2013, the Board of Directors (the “Board”) appointed Raymond J. Furey as the Senior Vice President and Chief Compliance Officer of the Company. 5.07 On May 24, 2013, Questcor Pharmaceuticals, Inc. (the “Company”) held its 2013 Annual Meeting of Shareholders (the “Annual Meeting”). | d546949d8k.htm |
| 2013-05-14 | 8-K | 2013-05-14 | 7.01 Regulation FD Disclosure | 7.01 Commencing on May 14, 2013, Questcor Pharmaceuticals, Inc. will utilize an updated presentation for investor relations purposes. | d537935d8k.htm |
| 2013-05-06 | 8-K | 2013-04-30 | 2.02 Results of Operations and Financial Condition | 2.02 On April 30, 2013, Questcor Pharmaceuticals, Inc. (the “Company”) announced via press release certain operating and financial results for the quarter ended March 31, 2013. | d532666d8k.htm |
| 2013-04-03 | 8-K/A | 2013-01-18 | 2.01 Completion of Acquisition or Disposition of Assets | 2.01 This Amendment to Current Report on Form 8-K/A (the “Amendment”) is being filed to amend the Current Report on Form 8-K filed by Questcor Pharmaceuticals, Inc. (the “Company”) with the U.S. Securities and Exchange Commission on January 18, 2013 (the “Original Form 8-K”) regarding the acquisition by Questcor, through a wholly-owned subsidiary, of all of the issued and outstanding shares of BioVectra Inc. (“BioVectra”). | a8-kaproforma.htm |
| 2013-03-04 | 8-K | 2013-02-26 | 2.02 Results of Operations and Financial Condition | 2.02 On February 26, 2013, Questcor Pharmaceuticals, Inc. (the “Company”) announced via press release certain operating and financial results for the quarter and year ended December 31, 2012. | d495264d8k.htm |
| 2013-01-18 | 8-K | 2013-01-18 | 2.01 Completion of Acquisition or Disposition of Assets | 2.01 On January 4, 2013, Questcor Pharmaceuticals, Inc. (“Questcor”) filed a Current Report on Form 8-K disclosing that on January 2, 2013, Questcor and its wholly owned subsidiary (“Acquisition Co.”), entered into a Share Purchase Agreement (the “Agreement”) to acquire all of the issued and outstanding shares of BioVectra Inc. (“BioVectra”). | d467354d8k.htm |
| 2013-01-09 | 8-K | 2013-01-09 | 7.01 Regulation FD Disclosure | 7.01 Commencing on January 9, 2013, Questcor Pharmaceuticals, Inc. (the “Company”) will utilize an updated presentation for investor relations purposes. | d464037d8k.htm |
| 2013-01-04 | 8-K | 2013-01-02 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On January 2, 2013, Questcor and BioVectra issued a joint press release announcing the entry into the Agreement. | d458579d8k.htm |